
Avanos Medical AVNS
$ 24.73
0.47%
Quarterly report 2026-Q1
added 05-05-2026
Avanos Medical Gross Profit 2011-2026 | AVNS
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 354 M | 381 M | 380 M | 394 M | 366 M | 371 M | 402 M | 391 M | 337 M | 558 M | 532 M | 549 M | 612 M | 602 M | 591 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 612 M | 337 M | 455 M |
Quarterly Gross Profit Avanos Medical
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.2 M | - | 86 M | 92.1 M | 89.8 M | - | 92.9 M | 95.6 M | 94.8 M | - | 95.5 M | 97.8 M | 91.4 M | - | 100 M | 102 M | 107 M | - | 90.2 M | 85.7 M | 91.3 M | - | 95.8 M | 86.5 M | 102 M | - | 95 M | 98.7 M | 98.8 M | - | 105 M | 94.7 M | 91.1 M | - | 81 M | 84.5 M | 81.5 M | - | 138 M | 141 M | 136 M | - | 131 M | 135 M | 132 M | - | 132 M | 105 M | 155 M | - | 162 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 162 M | 81 M | 105 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
275 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
22.7 M | $ 11.72 | 2.45 % | $ 332 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
532 M | $ 8.02 | -3.02 % | $ 1.2 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 4.35 | 1.16 % | $ 163 M | ||
|
BioSig Technologies
BSGM
|
18 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
5.52 M | $ 2.3 | 0.22 % | $ 50.7 M | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
19.2 M | $ 1.04 | 2.96 % | $ 17.6 M | ||
|
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.47 | 1.78 % | $ 29.2 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 17.98 | -2.12 % | $ 422 M | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 10.8 | -2.04 % | $ 387 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 5.96 | -2.13 % | $ 71.3 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
940 M | $ 75.51 | 2.28 % | $ 4.12 B | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.55 | -0.32 % | $ 63.1 M | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
MiMedx Group
MDXG
|
346 M | $ 3.68 | 1.52 % | $ 544 M | ||
|
Electromed
ELMD
|
50 M | $ 38.07 | -0.39 % | $ 322 M | ||
|
Myomo
MYO
|
26.9 M | $ 1.02 | -1.44 % | $ 42.7 M | ||
|
Butterfly Network
BFLY
|
45.7 M | $ 4.56 | 1.9 % | $ 1.13 B | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
566 M | $ 9.68 | -9.95 % | $ 383 M | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
1.02 B | $ 85.23 | 0.5 % | $ 11.5 B | ||
|
Profound Medical Corp.
PROF
|
11.4 M | $ 6.89 | 0.88 % | $ 208 M | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 153.27 | -1.03 % | $ 10.8 B | ||
|
CONMED Corporation
CNMD
|
750 M | $ 36.17 | -2.85 % | $ 1.12 B | ||
|
Sintx Technologies
SINT
|
461 K | $ 2.43 | 1.67 % | $ 6.74 M | ||
|
Inspire Medical Systems
INSP
|
779 M | $ 42.2 | -3.74 % | $ 1.24 B | ||
|
Integer Holdings Corporation
ITGR
|
500 M | $ 90.97 | 1.89 % | $ 3.16 B | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 87.78 | 2.33 % | $ 51.3 B | ||
|
TransMedics Group
TMDX
|
363 M | $ 70.27 | 1.94 % | $ 2.39 B |